Migraine Trial, Recruiting (NCT06628921)

Migraine Trial, Recruiting NCT06628921 Sponsor: University of Florence Condition: Migraine

Printed from Voxsanity (voxsanity.com.au) — NCT06628921 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Migraine

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People who have been diagnosed with migraine without aura, migraine with aura, or chronic migraine, as defined by the standard international headache diagnostic guidelines (ICHD-III).
People who experience at least 8 days of migraine per month.
People who are willing and able to follow the study procedures as required.
People who have been keeping a migraine diary for at least one month before enrolling.
People who have a migraine attack currently in progress at the time of treatment administration.
People who are already enrolled in a related study called TACHIS (NCT06409845).

Who may not be able to join:

People for whom the study drug, eptinezumab, is medically unsuitable or contraindicated.
People with other medical conditions or health issues that, in the treating doctor's opinion, could affect the study's results or assessments.
People who are pregnant or breastfeeding.
People who have made changes to their existing migraine prevention medication in the month before starting eptinezumab.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 20 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 06 225411

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06628921

Sponsor: University of Florence

Phase: Not Applicable

Status: Recruiting

Condition: Migraine

Trial contact: 06 225411

More information: https://clinicaltrials.gov/study/NCT06628921

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People who have been diagnosed with migraine without aura, migraine with aura, or chronic migraine, as defined by the standard international headache diagnostic guidelines (ICHD-III).
People who experience at least 8 days of migraine per month.
People who are willing and able to follow the study procedures as required.
People who have been keeping a migraine diary for at least one month before enrolling.
People who have a migraine attack currently in progress at the time of treatment administration.
People who are already enrolled in a related study called TACHIS (NCT06409845).

Who may not be able to join:

People for whom the study drug, eptinezumab, is medically unsuitable or contraindicated.
People with other medical conditions or health issues that, in the treating doctor's opinion, could affect the study's results or assessments.
People who are pregnant or breastfeeding.
People who have made changes to their existing migraine prevention medication in the month before starting eptinezumab.

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 20 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

University of Florence

Registry

ClinicalTrials.gov

Start date

30 October 2024

Est. completion

30 October 2026

Where this trial is recruiting

🇮🇹 Italy

Primary endpoints

Time to Headache Pain Freedom

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov